- Home
- ACFN vs ANL Comparison
ACFN vs ANL Comparison
Compare ACFN & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACFN
- ANL
- Stock Information
- Founded
- ACFN 1986
- ANL 2004
- Country
- ACFN United States
- ANL Cayman Islands
- Employees
- ACFN N/A
- ANL N/A
- Industry
- ACFN Military/Government/Technical
- ANL
- Sector
- ACFN Consumer Discretionary
- ANL
- Exchange
- ACFN Nasdaq
- ANL Nasdaq
- Market Cap
- ACFN 63.5M
- ANL 61.8M
- IPO Year
- ACFN N/A
- ANL 2023
- Fundamental
- Price
- ACFN $25.11
- ANL $1.51
- Analyst Decision
- ACFN
- ANL Hold
- Analyst Count
- ACFN 0
- ANL 1
- Target Price
- ACFN N/A
- ANL N/A
- AVG Volume (30 Days)
- ACFN 15.4K
- ANL 6.5K
- Earning Date
- ACFN 11-10-2025
- ANL 11-11-2025
- Dividend Yield
- ACFN N/A
- ANL N/A
- EPS Growth
- ACFN 1520.82
- ANL N/A
- EPS
- ACFN 2.84
- ANL N/A
- Revenue
- ACFN $13,202,000.00
- ANL N/A
- Revenue This Year
- ACFN N/A
- ANL N/A
- Revenue Next Year
- ACFN N/A
- ANL N/A
- P/E Ratio
- ACFN $8.82
- ANL N/A
- Revenue Growth
- ACFN 50.98
- ANL N/A
- 52 Week Low
- ACFN $17.22
- ANL $1.10
- 52 Week High
- ACFN $33.00
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- ACFN 45.65
- ANL 34.86
- Support Level
- ACFN $23.00
- ANL $1.55
- Resistance Level
- ACFN $26.47
- ANL $1.67
- Average True Range (ATR)
- ACFN 1.74
- ANL 0.09
- MACD
- ACFN -0.04
- ANL -0.02
- Stochastic Oscillator
- ACFN 46.89
- ANL 12.00
About ACFN Acorn Energy Inc. Common Stock
Acorn Energy Inc is a holding company that focuses on technology-driven solutions for energy infrastructure asset management. It operates through two segments namely, the PG segment and the CP segment. PG segment provides wireless remote monitoring and control systems and services for critical assets as well as Internet of Things applications which account for the majority of the revenue. CP segment is engaged in providing remote monitoring of cathodic protection systems on gas pipelines for gas utilities and pipeline companies.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.